CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Learn what's the best investment strategy to help you maximize your returns and achieve your financial goals.
22,631 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
This year has brought a 28% pullback for Reddit, raising questions about its growth and future. But stocks don’t move...
The AI era hinges on faster data movement and scalable hardware. This article explains why optical networking could b...
Moderna’s growth story now centers on a broader mRNA pipeline and FDA decisions. This guide breaks down the upcoming ...
The Massachusetts Supreme Judicial Court unanimously blocked a statewide rent stabilization petition from the 2026 ba...
With crude hovering near $70, some investors wonder if energy stocks can keep delivering. This article explains why t...
Regulators curb junk fees and interest-rate pressures push operators to monetize services. The amenity arms race over...
Nipsey Hussle’s children have now received half of their father’s estate after a lengthy probate. This article explai...
As July 18, 2026 approaches, the GENIUS Act deadline accelerates rulemaking for stablecoin issuers. Regulators from T...
Two heavyweights vie for leadership in AI cooling and data-center resilience. This guide breaks down which stock—NVEN...
When a blue-chip stock posts a stunning earnings beat, investors flock to understand what comes next. This guide brea...
Across Chicago and beyond, AI readiness in schools mirrors economic divides. This report examines funding gaps, acces...